Clinical Trial Update: A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

View source ↗

Summary

This clinical trial update reports the completion of a study evaluating the effectiveness and safety of Mayzent (fingolimod) in Chinese patients with relapsing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Progressive Multiple Sclerosis
• Relapsing Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Sponsor: Novartis | Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Status: COMPLETED